Dental Care Clinics in Mackay, ID Accepting Medicare
3 Dental Care Clinics found. Showing 1 - 3
 Two Rivers Dental, Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 304 S Main St, Mackay, ID 83251 Phone: 208-588-3316 Fax: 208-588-3166 |
Summit View Dental Services Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 211 E Custer St, Mackay, ID 83251 Phone: 208-588-3316 Fax: 208-588-3316 |
O-bar Family Dental Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 304 So Main, Mackay, ID 83251 Phone: 208-588-3316 Fax: 208-588-3166 |
News Archive
Pennington Biomedical awarded $4.5 million funding to evaluate treatments for childhood obesity
A research team at LSU's Pennington Biomedical Research Center has been approved for a five-year, $4.5 million funding award by the Patient-Centered Outcomes Research Institute, or PCORI, to evaluate two treatments for children who have obesity.
NYU Langone completes robotic surgery education sessions
The Robotic Surgery Center at NYU Langone Medical Center recently completed its second year offering monthly robotic surgery education sessions for minimally invasive robotic procedures.
Toxic man-made chemicals that end up in the environment highlight regulation challenges
Researchers at the University of New Hampshire have conducted two of the first studies in New England to collectively show that toxic man-made chemicals called PFAS (per-and polyfluoroalkyl substances), found in everything from rugs to product packaging, end up in the environment differently after being processed through wastewater treatment facilities-making it more challenging to set acceptable screening levels.
AVEO Pharmaceuticals presents tivozanib's Phase 2 trial data at ASCO meeting
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
New investigational drug offers potential treatment option for lung cancer
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
› Verified 1 days ago